Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope

N. L. Letvin, S. Robinson, D. Rohne, Michael Axthelm, J. W. Fanton, M. Bilska, T. J. Palker, H. X. Liao, B. F. Haynes, D. C. Montefiori

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Vaccine-elicited antibodies specific for the third hypervariable domain of the surface gp120 of human immunodeficiency virus type 1 (HIV-1) (V3 loop) were assessed for their contribution to protection against infection in the simian-human immunodeficiency virus (SHIV)/rhesus monkey model. Peptide vaccine-elicited anti-V3 loop antibody responses were examined for their ability to contain replication of SHIV-89.6, a nonpathogenic SHIV expressing a primary patient isolate HIV-1 envelope, as well as SHIV-89.6P, a pathogenic variant of that virus. Low-titer neutralizing antibodies to SHIV-89.6 that provided partial protection against viremia following SHIV-89.6 infection were generated. A similarly low-titer neutralizing antibody response to SHIV-89.6P that did not contain viremia after infection with SHIV-89.6P was generated, but a trend toward protection against CD4+ T-lymphocyte loss was seen in these infected monkeys. These observations suggest that the V3 loop on some primary patient HIV-1 isolates may be a partially effective target for neutralizing antibodies induced by peptide immunogens.

Original languageEnglish (US)
Pages (from-to)4165-4175
Number of pages11
JournalJournal of Virology
Volume75
Issue number9
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Simian Immunodeficiency Virus
Human immunodeficiency virus
Human immunodeficiency virus 1
Macaca mulatta
HIV-1
Vaccines
HIV
vaccines
antibodies
Antibodies
neutralizing antibodies
Neutralizing Antibodies
viremia
Viremia
Antibody Formation
subunit vaccines
HIV infections
Subunit Vaccines
infection
Virus Diseases

ASJC Scopus subject areas

  • Immunology

Cite this

Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. / Letvin, N. L.; Robinson, S.; Rohne, D.; Axthelm, Michael; Fanton, J. W.; Bilska, M.; Palker, T. J.; Liao, H. X.; Haynes, B. F.; Montefiori, D. C.

In: Journal of Virology, Vol. 75, No. 9, 2001, p. 4165-4175.

Research output: Contribution to journalArticle

Letvin, N. L. ; Robinson, S. ; Rohne, D. ; Axthelm, Michael ; Fanton, J. W. ; Bilska, M. ; Palker, T. J. ; Liao, H. X. ; Haynes, B. F. ; Montefiori, D. C. / Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. In: Journal of Virology. 2001 ; Vol. 75, No. 9. pp. 4165-4175.
@article{1261b89efe124cb39188859076de47ce,
title = "Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope",
abstract = "Vaccine-elicited antibodies specific for the third hypervariable domain of the surface gp120 of human immunodeficiency virus type 1 (HIV-1) (V3 loop) were assessed for their contribution to protection against infection in the simian-human immunodeficiency virus (SHIV)/rhesus monkey model. Peptide vaccine-elicited anti-V3 loop antibody responses were examined for their ability to contain replication of SHIV-89.6, a nonpathogenic SHIV expressing a primary patient isolate HIV-1 envelope, as well as SHIV-89.6P, a pathogenic variant of that virus. Low-titer neutralizing antibodies to SHIV-89.6 that provided partial protection against viremia following SHIV-89.6 infection were generated. A similarly low-titer neutralizing antibody response to SHIV-89.6P that did not contain viremia after infection with SHIV-89.6P was generated, but a trend toward protection against CD4+ T-lymphocyte loss was seen in these infected monkeys. These observations suggest that the V3 loop on some primary patient HIV-1 isolates may be a partially effective target for neutralizing antibodies induced by peptide immunogens.",
author = "Letvin, {N. L.} and S. Robinson and D. Rohne and Michael Axthelm and Fanton, {J. W.} and M. Bilska and Palker, {T. J.} and Liao, {H. X.} and Haynes, {B. F.} and Montefiori, {D. C.}",
year = "2001",
doi = "10.1128/JVI.75.9.4165-4175.2001",
language = "English (US)",
volume = "75",
pages = "4165--4175",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope

AU - Letvin, N. L.

AU - Robinson, S.

AU - Rohne, D.

AU - Axthelm, Michael

AU - Fanton, J. W.

AU - Bilska, M.

AU - Palker, T. J.

AU - Liao, H. X.

AU - Haynes, B. F.

AU - Montefiori, D. C.

PY - 2001

Y1 - 2001

N2 - Vaccine-elicited antibodies specific for the third hypervariable domain of the surface gp120 of human immunodeficiency virus type 1 (HIV-1) (V3 loop) were assessed for their contribution to protection against infection in the simian-human immunodeficiency virus (SHIV)/rhesus monkey model. Peptide vaccine-elicited anti-V3 loop antibody responses were examined for their ability to contain replication of SHIV-89.6, a nonpathogenic SHIV expressing a primary patient isolate HIV-1 envelope, as well as SHIV-89.6P, a pathogenic variant of that virus. Low-titer neutralizing antibodies to SHIV-89.6 that provided partial protection against viremia following SHIV-89.6 infection were generated. A similarly low-titer neutralizing antibody response to SHIV-89.6P that did not contain viremia after infection with SHIV-89.6P was generated, but a trend toward protection against CD4+ T-lymphocyte loss was seen in these infected monkeys. These observations suggest that the V3 loop on some primary patient HIV-1 isolates may be a partially effective target for neutralizing antibodies induced by peptide immunogens.

AB - Vaccine-elicited antibodies specific for the third hypervariable domain of the surface gp120 of human immunodeficiency virus type 1 (HIV-1) (V3 loop) were assessed for their contribution to protection against infection in the simian-human immunodeficiency virus (SHIV)/rhesus monkey model. Peptide vaccine-elicited anti-V3 loop antibody responses were examined for their ability to contain replication of SHIV-89.6, a nonpathogenic SHIV expressing a primary patient isolate HIV-1 envelope, as well as SHIV-89.6P, a pathogenic variant of that virus. Low-titer neutralizing antibodies to SHIV-89.6 that provided partial protection against viremia following SHIV-89.6 infection were generated. A similarly low-titer neutralizing antibody response to SHIV-89.6P that did not contain viremia after infection with SHIV-89.6P was generated, but a trend toward protection against CD4+ T-lymphocyte loss was seen in these infected monkeys. These observations suggest that the V3 loop on some primary patient HIV-1 isolates may be a partially effective target for neutralizing antibodies induced by peptide immunogens.

UR - http://www.scopus.com/inward/record.url?scp=0035043246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035043246&partnerID=8YFLogxK

U2 - 10.1128/JVI.75.9.4165-4175.2001

DO - 10.1128/JVI.75.9.4165-4175.2001

M3 - Article

VL - 75

SP - 4165

EP - 4175

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 9

ER -